Journal
FEBS JOURNAL
Volume 288, Issue 1, Pages 10-35Publisher
WILEY
DOI: 10.1111/febs.15558
Keywords
cancer; exosomes; immunotherapy; lymphoid cells; myeloid cells
Categories
Funding
- Odyssey Program
- Theodore N. Law for Scientific Achievement at the University of Texas MD Anderson Cancer Center
- University of Texas MD Anderson Cancer Center
- NCI [RO1 CA213233, RO1 CA195733, CA231465]
Ask authors/readers for more resources
Exosomes play crucial roles in cancer by either promoting tumor development or inhibiting tumor immune suppression. They deliver signals that affect immune regulation of lymphoid and myeloid cell populations in tumors.
Exosomes are nanosized extracellular vesicles of endosomal origin that enclose a multitude of functional biomolecules. Exosomes have emerged as key players of intercellular communication in physiological and pathological conditions. In cancer, depending on the context, exosomes can oppose or potentiate the development of an aggressive tumor microenvironment, thereby impacting tumor progression and clinical outcome. Increasing evidence has established exosomes as important mediators of immune regulation in cancer, as they deliver a plethora of signals that can either support or restrain immunosuppression of lymphoid and myeloid cell populations in tumors. Here, we review the current knowledge related to exosome-mediated regulation of lymphoid (T lymphocytes, B lymphocytes, and NK cells) and myeloid (macrophages, dendritic cells, monocytes, myeloid-derived suppressor cells, and neutrophils) cell populations in cancer. We also discuss the translational potential of engineered exosomes as immunomodulatory agents for cancer therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available